JamesWeisbergerMD
Pathology • Elmwood Park, NJHematopathology, Anatomic Pathology, Clinical Pathology
Physician
Are you Dr. Weisberger?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
481 Edward H Ross Dr
Elmwood Park, NJ 07407Phone+1 201-791-2600
Summary
- Dr. James Weisberger, MD is a board certified pathologist in Elmwood Park, New Jersey. He is currently licensed to practice medicine in New Jersey, Virginia, and District of Columbia.
Education & Training
Perelman School of Medicine at the University of PennsylvaniaClass of 1983
Certifications & Licensure
NM State Medical License 2008 - 2027
VA State Medical License 2020 - 2026
FL State Medical License 2008 - 2026
PA State Medical License 2008 - 2026
NY State Medical License 1991 - 2026
AR State Medical License 2009 - 2026
NJ State Medical License 1999 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Pathology Anatomic Pathology & Clinical Pathology- American Board of Pathology Hematology
- Join now to see all
Publications & Presentations
PubMed
- 108 citationsViral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies.Stephen M Kissler, Joseph R. Fauver, Christina D. Mack, Scott W. Olesen, Caroline G. Tai
Plos Biology. 2021-07-12 - 3 citationsPerformance of the 4Kscore Test in Plasma and Serum and Stability of the Component Analytes in Clinical SamplesChristina E Higgins, Patricia Neybold, Marcella B Holdridge, Catherine R Barnes, Yan Dong
The Journal of Applied Laboratory Medicine. 2018-09-01 - 1 citationsA case of lenalidomide-dependent myelodysplastic syndrome.Ira Miller, Wei-Tong Hsu, James Weisberger, Parameswaran Venugopal
Blood Advances. 2017-06-30
Press Mentions
OPKO Health’s BioReference Laboratories to Participate in the National Cancer Institute NCI-MATCH (Molecular Analysis for Therapy Choice) Phase II Clinical TrialAugust 28th, 2018
NKF Collaborates with Laboratories, Societies to Standardize Testing for CKDFebruary 21st, 2018
Letters, 9/17September 18th, 2017- Join now to see all
